

CURE

Beyond
CIRM 2.0
CALIFORNIA'S STEM CELL AGENCY

now it's personal

INCEPTION PROGRAM

Gil Sambrano, Ph.D.

Vice President Portfolio Development
and Review



HOPE

Funding Opportunities



DISCOVERY



TRANSLATION



CLINICAL

New Idea



Single Product Candidate



Pre-IND Meeting or Equivalent



Approved Therapy



1-2/Year



3/Year



12/Year

Program Offerings Per Year

CIRM 2.0 Inception Program



Objective

Provide **seed funding** for **great ideas** that may impact the field of human stem cell research but need modest support to test and compete for larger funding opportunities.

Emphasis of GWG Review



- “**Great new ideas**” with potential to ultimately result in a translatable human stem/progenitor cell-based product or technology.
- Ideas with a sound scientific rationale is important, but **preliminary data are not required or expected**. This is a high risk, high reward program.
- We will provide **\$150K to test the idea** and generate data to compete for larger (more substantial) funding opportunities through CIRM or other sources.

Scoring System



- **Tier 1: Score of “85-100”**

Exceptional merit and warrants funding, if funds are available.

- **Tier 2: Score of “1-84”**

Not recommended for funding.

Applications are scored by all scientific members of the GWG with no conflict.

DISC 1: GWG Recommendations



	DISC1 Apps	Total Applicant Request
Tier 1: Score 85-100 Exceptional merit and warrants funding, if funds available	13	\$2,871,984
Tier 2: Score 1-84 Not recommended for funding	28	

Overview of Recommended Applications

DISC1-10603



TITLE: iPSC-Derived Smooth Muscle Progenitors for Treatment of Abdominal Aortic Aneurysm

UTILITY/DISEASE TARGET: Aortic aneurysm

PRODUCT TYPE: Cell therapy

DISC1-10475

TITLE: Generation of human airway stem cells by direct transcriptional reprogramming for disease modeling and regeneration

UTILITY/DISEASE TARGET: Respiratory diseases

PRODUCT TYPE: In vitro disease model

DISC1-10643



TITLE: IVD rejuvenation using iPSC-derived notochordal cells

UTILITY/DISEASE TARGET: Intervertebral disc degeneration

PRODUCT TYPE: Cell therapy

DISC1-10598



TITLE: Enhanced Branching Morphogenesis and Pluripotent Cell Lineage Differentiation for Pediatric Regenerative Therapies

UTILITY/DISEASE TARGET: Kidney disease

PRODUCT TYPE: Combination cell/scaffold therapy

DISC1-10583



TITLE: Human Pancreatic Cancer Stem Cells:
Developing a Novel Drug for Cancer Eradication

UTILITY/DISEASE TARGET: Pancreatic cancer

PRODUCT TYPE: Small molecule drug

DISC1-10555



TITLE: Optimizing self-renewal signaling kinetics to stabilize ex vivo hematopoietic stem cell expansion

UTILITY/DISEASE TARGET: Blood stem cell expansion

PRODUCT TYPE: Cell maintenance system

DISC1-10620



TITLE: Bone Marrow Targeting of Hematopoietic Stem Cells Engineered to Overexpress 25-OH-VD3 1- α -hydroxylase for Acute Myeloid Leukemia Therapy

UTILITY/DISEASE TARGET: Acute myeloid leukemia

PRODUCT TYPE: Gene-modified cell therapy

DISC1-10513



TITLE: Novel metabolic labeling method for tracking stem cells to irradiated salivary glands using PET

UTILITY/DISEASE TARGET: In vivo stem cell tracking

PRODUCT TYPE: Cell labeling methodology

DISC1-10522

TITLE: Identification of antigenic neo-epitopes from in vitro reprogrammed human tissue precursors for regenerative therapy

UTILITY/DISEASE TARGET: Immunogenicity of reprogrammed cells

PRODUCT TYPE: Tools to assess immune rejection

DISC1-10588

TITLE: Targeting cancer stem cells with nanoparticle RNAi delivery to prevent recurrence and metastasis of ovarian cancer

UTILITY/DISEASE TARGET: Ovarian cancer

PRODUCT TYPE: Nanoparticle RNAi

DISC1-10721



TITLE: An iPSC cell based model of macular degeneration for drug discovery

UTILITY/DISEASE TARGET: Age-related macular degeneration

PRODUCT TYPE: Cell-based drug screening tool

DISC1-10516



TITLE: Development of treatments to improve healing of ischemic wounds

UTILITY/DISEASE TARGET: Diabetic foot ulcers

PRODUCT TYPE: Combination cell/scaffold therapy

DISC1-10718



TITLE: Gingival mesenchymal stem cells as a novel treatment modality for periodontal tissue regeneration

UTILITY/DISEASE TARGET: Periodontitis

PRODUCT TYPE: Combination cell/scaffold therapy